Summary There is evidence that predisposition to cancer has a genetic component. Genetic models have suggested that there is at least one highly penetrant gene predisposing to this disease. The oncogene MXI1 on chromosome band 10q24-25 is mutated in a proportion of prostate tumours and loss of heterozygosity occurs at this site, suggesting the location of a tumour suppressor in this region. To investigate the possibility that MXI1 may be involved in inherited susceptibility to prostate cancer, we have sequenced the HLH and ZIP regions of the gene in 38 families with either three cases of prostate cancer or two affected siblings both diagnosed below the age of 67 years. These are the areas within which mutations have been described in some sporadic prostate cancers. No mutations were found in these two important coding regions and we therefore conclude that MXll does not make a major contribution to prostate cancer susceptibility.
Prostate cancer is the second commonest cause of cancer mortality in men in the UK (OPCS figures, 1993) . Its incidence is increasing by more than 10% every 5 years (Coleman et al, 1993) , even when the effect of screening is taken into account, and approximately 13% of cases occur in men under 65 years. There is increasing evidence that there is an inherited component to many of the common cancers (Easton and Peto, 1990) , and prostate cancer is no exception. There are several lines of evidence for this: familial clustering of prostate cancer has been observed, most dramatically in the large prostate cancer kindreds described in Utah, USA (Eeles and Cannon Albright, 1996) ; relatives of cases have an increased relative risk of developing the disease compared with relatives of control subjects in case-control studies (reviewed in Eeles, 1995) , and this has been confirmed in two cohort studies (Goldgar et al, 1994; Gronberg et al, 1996) . This relative risk increases markedly when the age of the index case decreases or the number of affected subjects in a cluster increases, which is evidence that this increase in risk has a genetic component. Segregation analysis has led to the proposed model of at least one highly penetrant gene (88% of the gene carriers would develop prostate cancer by age 85 years), which accounts for 43% of cases diagnosed at less than 55 years (Carter et al, 1992) . When prostate cancer susceptibility genes are located, men at increased risk of the disease, particularly at a younger age, will be able to be identified. A prostate cancer susceptibility locus has recently been reported on lq24-25 (Smith et al, 1996) ; however, this would only account for 34% of families, and further susceptibility loci remain to be identified. Received 29 October 1996 Revised 17 March 1997 Accepted 26 March 1997 Correspondence to: RA Eeles To date, with the exception of MEN2 due to RET (Mulligan et al, 1994) , all high-risk cancer predisposition genes are tumour suppressors; one allele is inherited in a mutated form and tumour development occurs when the remaining allele at the cancer predisposition locus is inactivated by loss or mutation (Knudson, 1985) . If prostate cancer follows the same model, candidates for susceptibility genes would reside in the areas of loss of heterozygosity (LOH) observed in prostate tumours.
The long arm of chromosome 10 is the fourth commonest area demonstrating LOH in sporadic prostate cancers (reviewed in Eeles, 1995) . In a study of 42 informative tumours, LOH at 10qter was observed in 19% of cases (Steinberg et al, 1990) and, more recently, Eagle et al (1995) documented mutation at the nondeleted MXII locus, which is in this region, in four out of ten prostate cancers that had LOH at 10q24-25. Furthermore, in one sample with no cytogenetic abnormality, the MXII gene was shown to be absent. The mutations are in the non-deleted HLH and ZIP exons, which are the parts of the gene that code for the helixloop-helix and leucine zipper regions involved in protein dimerization. This is needed for specificity of MXII action. However, Gray et al (1995) subsequently failed to find any mutations in MXI in tumour DNA from 37 prostate cancers.
The oncogene, MYC, has been shown to be overexpressed in higher-grade prostate cancers (Buttyan et al, 1987) No mutations of MXI 1 in prostate cancer clusters 993 Reverse 5'-CGC GM TTC ACC AGA ACT GAG GGA ATT GTG function mediated by a highly basic region adjacent to the HLH-ZIP motif (Murre et al, 1989) . MYC also has distinct transcriptional activation domains, which modulate gene expression (Kato et al, 1990) . MAX forms heterodimers with MXI1 (Zervos et al, 1993) and this inhibits MYC function in two ways: first, by sequestering MAX (preventing the formation of MAX-MYC heterodimers); and, secondly, by competing with MAX-MYC heterodimers for binding to target sites (Zervos et al, 1993) . Taken Arrowed case: individual whose DNA was sequenced PCR products were purified before dye terminator cycle sequencing according to Hamoudi et al (1996) . The DNA was dissolved in 12-15 p1 of water and 3-4 gl was run on a 2% agarose gel to check for the presence and purity of the product.
Cycle sequencing PCR products were purified as above and sequenced directly using an ABI prism dye terminator cycle sequencing ready reaction kit (Perkin Elmer), as recommended in the instructions, with thermocycling as follows: 25 cycles of 96°C for 30 s, 50°C for 15 s and 60°C for 4 min. After thermocycling, the extension products were removed from beneath the oil and added to 2 p1 of 3 M sodium acetate, pH 5.2, precipitated with 50 gd of absolute ethanol and centrifuged. The pellet was washed with 70% ethanol, dried, then stored at -20°C before automated sequencing.
Automated sequencing
The HLH and ZIP exons of the MXII gene were sequenced both in the forward and reverse directions using the appropriate primer shown in Table 1 . Sequencing was conducted on a 6%
British Journal of Cancer (1997) 76(8) polyacrylamide denaturing gel (Biorad) in a 1 x TBE (Tris borate buffer) using an ABI 373A automated fluorescent DNA sequencer. The DNA pellet was dissolved in 4 jl of formamide. This mix was denatured for 2 min at 92°C and loaded into each well. The gel was run for 10 h at 30 W, 40 mA and 2500 V. During electrophoresis, the fluorescence was detected in the laser scanner region using filter set A and data were collected and stored using the DNA Sequencing Analysis Software (v.1.2; ABI, CA, USA). On completion of the gel run, the data were analysed further using Factura and Sequence Navigator software (ABI). Eagle et al (1995) , which included one intronic mutation, were not observed. On the basis of these observations, the upper 95% confidence limit for the proportion of families with MXII mutations in ZIP and HLH would be 7.6% and therefore, assuming that familial prostate cancer is mediated by a single dominant gene as predicted by the Carter model, MXII muta- 
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